| Literature DB >> 34093698 |
Hock Ing Chiu1, Che Nurul Azieyan Che Mood1, Nur Nadhirah Mohamad Zain1, Muggundha Raoov Ramachandran2, Noorfatimah Yahaya1, Nik Nur Syazni Nik Mohamed Kamal1, Wai Hau Tung3, Yoke Keong Yong4, Chee Keong Lee5, Vuanghao Lim1.
Abstract
Silver nanoecies">particles (Entities:
Year: 2021 PMID: 34093698 PMCID: PMC8140852 DOI: 10.1155/2021/9920890
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Inhibition zones (mm) of the biosynthesised silver nanoparticles against microorganisms using the disc diffusion method (mean ± SD, n = 3); mean values are significantly different (p < 0.05) between tested samples in each particular bacterium/fungus with different lower case superscript letters a, b, c, and d.
| Samples | Inhibition zone (mm) | ||||||
|---|---|---|---|---|---|---|---|
| Gram-positive bacteria | Gram-negative bacteria | Fungi | |||||
| SA | SE | SP | EC | PA | CA | CG | |
| CNL | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| CNS | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| AgNP-L | 11.350 ± 0.243b | 11.597 ± 0.311b | 10.260 ± 0.125b | 9.220 ± 0.433b | 10.073 ± 0.280b | 0.000a | 0.000a |
| AgNP-S | 11.517 ± 0.519b | 10.153 ± 0.232c | 10.493 ± 0.345b | 9.247 ± 0.081b | 10.000 ± 0.305b | 0.000b | 0.000a |
| C-AgNP | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000b | 0.000a |
| dH2O | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000b | 0.000a |
| Gentamycin | 21.957 ± 0.486c | 25.543 ± 0.440d | 22.967 ± 0.799c | 21.840 ± 0.155c | 17.530 ± 0.521c | ND | ND |
| Nystatin | ND | ND | ND | ND | ND | 17.367 ± 0.136c | 21.200 ± 0.200b |
ND = not determined.
Inhibition zones (mm) of the biosynthesised silver nanoparticles against tested microorganisms using the well diffusion method (mean ± SD, n = 3); mean values are significantly different (p < 0.05) between tested samples in each particular bacterium/fungus with different lower case superscript letters a, b, c, and d.
| Samples | Zone of inhibition (mm) | ||||||
|---|---|---|---|---|---|---|---|
| Gram-positive bacteria | Gram-negative bacteria | Fungi | |||||
| SA | SE | SP | EC | PA | CA | CG | |
| CNL | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| CNS | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| AgNaP-L | 18.290 ± 0.303b | 16.987 ± 0.652b | 13.913 ± 0.311b | 12.830 ± 0.607b | 14.160 ± 0.436b | 0.000a | 0.000a |
| AgNaP-S | 17.237 ± 0.123c | 17.000 ± 0.146b | 13.730 ± 0.191b | 13.413 ± 4.500b | 14.140 ± 4.500b | 0.000a | 0.000a |
| C-AgNaPs | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| Gentamycin | 27.81 ± 0.206d | 31.84 ± 0.138c | 26.42 ± 0.678c | 24.45 ± 0.116c | 26.78 ± 0.102c | ND | ND |
| dH2O | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a | 0.000a |
| Nystatin | ND | ND | ND | ND | ND | 26.267 ± 4.500b | 31.285 ± 5.511b |
ND = not determined.
MIC and MBC of tested samples against microorganisms.
| Samples | MIC ( | MBC ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SA | SE | SP | PA | EC | SA | SE | SP | PA | EC | |
| AgNP-L | 250 | 250 | 250 | 250 | 125 | 250 | 250 | 250 | 250 | 125 |
| AgNP-S | 250 | 250 | 250 | 125 | 125 | 250 | 250 | 250 | 125 | 125 |
| Gentamicin | 31.25 | 62.5 | 31.25 | 62.5 | 125 | 31.25 | 31.25 | 31.25 | 62.5 | 125 |
Figure 1(a) DPPH, (b) ABTS, and (c) FRAP assays. Samples with different lower case superscript letters differ significantly (p < 0.05) between them (mean ± SD, n = 3).
Figure 2Cell viability after 72 h at different concentrations (12.5–200 μg/mL) on (a) MCF-7, (b) HT-29, and (c) HeLa. The symbol (p < 0.05) represents the significant difference between the sample and control (untreated cells) (mean ± SD, n = 3).